Latest Market News

Iress Limited has responded to an ASX price query, denying any undisclosed information behind recent share price movements while acknowledging ongoing strategic discussions.

HeraMED has inked a 12-month commercial agreement with Philips’ U.S. subsidiary to deliver an integrated digital maternity care platform to American hospitals, combining cutting-edge monitoring devices with HeraMED’s remote patient monitoring technology.

Whitefield Income Limited has lowered the maximum issue price for its Share Purchase Plan to A$1.32 per share, reflecting recent market volatility and offering shareholders a notable discount.

Prospect Resources has completed the sale of its Step Aside Lithium Project in Zimbabwe for up to US$2.2 million, marking a strategic shift towards its larger copper venture in Zambia.

Iress Ltd has responded to recent media speculation about a potential acquisition, clarifying it cannot confirm any deal terms while continuing discussions with multiple parties.

Iondrive Limited has successfully raised $4 million through a share placement to accelerate the commercialisation of its innovative e-waste recycling technology in the United States.

Bendigo and Adelaide Bank has revealed systemic deficiencies in its anti-money laundering and counter-terrorism financing controls following a Deloitte investigation, committing to comprehensive remediation efforts.

IPD Group’s 2025 AGM reveals robust FY25 financial results driven by data centre and electrification sectors, alongside operational efficiencies and sustainability strides. The company signals continued momentum into FY26 with positive earnings guidance.

Whitefield Income Ltd reports robust first-quarter earnings and announces a $53 million capital raising via placement and a Share Purchase Plan, maintaining its focus on delivering steady, franked dividends.

L1 Long Short Fund Limited has updated its dividend notification to include the Dividend Reinvestment Plan price, confirming a fully franked quarterly payout and new issue securities.

Acrux Ltd reported a remarkable surge in licensing revenue from its topical generics portfolio alongside a strategic pivot towards innovative drug delivery R&D at its 2025 Annual General Meeting.

Aroa Biosurgery has reported a strong first half for FY26, with 14% revenue growth driven by its Myriad product line and a return to positive EBITDA. The company also secured relief from ASX quarterly reporting requirements, signaling improved financial stability.